TY - JOUR
T1 - Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions
T2 - its contribution to cytology.
AU - Canessa, Pier Aldo
AU - Franceschini, Maria Cristiana
AU - Ferro, Paola
AU - Battolla, Enrico
AU - Dessanti, Paolo
AU - Manta, Carmen
AU - Sivori, Massimiliano
AU - Pezzi, Riccardo
AU - Fontana, Vincenzo
AU - Fedeli, Franco
AU - Pistillo, Maria Pia
AU - Roncella, Silvio
PY - 2013/1
Y1 - 2013/1
N2 - Soluble mesothelin-related peptide (SMRP) is regarded as an FDA approved biomarker for the diagnosis and monitoring of pleural malignant mesothelioma (MPM). We detected the SMRP levels in pleural effusions (PE) by means of an ELISA and analyzed their diagnostic relevance to differentiate MPM from benign pathology and from non-MPM pleural metastasis. Comparison with cytology in MPM-PE was also performed. We found that SMRP detection in MPM-PE can help the diagnosis of MPM and provide additional diagnostic value to cytology. We concluded that SMRP test may be incorporated into clinical practice of PE from patients suspicious for MPM.
AB - Soluble mesothelin-related peptide (SMRP) is regarded as an FDA approved biomarker for the diagnosis and monitoring of pleural malignant mesothelioma (MPM). We detected the SMRP levels in pleural effusions (PE) by means of an ELISA and analyzed their diagnostic relevance to differentiate MPM from benign pathology and from non-MPM pleural metastasis. Comparison with cytology in MPM-PE was also performed. We found that SMRP detection in MPM-PE can help the diagnosis of MPM and provide additional diagnostic value to cytology. We concluded that SMRP test may be incorporated into clinical practice of PE from patients suspicious for MPM.
UR - http://www.scopus.com/inward/record.url?scp=84878258518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878258518&partnerID=8YFLogxK
U2 - 10.3109/07357907.2012.749265
DO - 10.3109/07357907.2012.749265
M3 - Article
C2 - 23249166
AN - SCOPUS:84872704685
SN - 0735-7907
VL - 31
SP - 43
EP - 50
JO - Cancer Investigation
JF - Cancer Investigation
IS - 1
ER -